Moderate TSH suppression may be better for patients with thyroid cancer
the ONA take:
According to a new study published online ahead of print in the journal Thyroid, researchers have found that moderate thyroid-stimulating hormone (TSH) suppression may be as beneficial as high suppression of the hormone responsible for driving thyroid cancer.
Higher TSH levels are associated with higher rates of thyroid cancer recurrence, but extreme suppression of TSH is linked with increased adverse events, such as arrhythmias and osteoporosis.
For the 30-year study, researchers analyzed data from 4,941 patients with thyroid cancer. Results showed that extreme TSH suppression offered no additional survival benefit compared with moderate TSH suppression in patients with high-risk disease. Moreover, researchers found that mild TSH suppression was beneficial for patients with low-risk thyroid cancer.
The findings suggest that further research is warranted to prospectively evaluate extreme TSH suppression versus moderate suppression in patients with high-risk thyroid cancer.
Moderate TSH suppression may be as beneficial as high suppression of the hormone responsible for driving the disease.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered
- The Bounty of Failure: A Well-Versed Nursing Experience
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|